Diligence memo · auto-generated · as of July 2, 2026

Spotlight Innovation, Inc.

Spotlight Innovation, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Spotlight Innovation, Inc. operates in Pharmaceuticals, based in West Des Moines.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Spotlight Innovation, Inc. has raised $44M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $41M on 2014-07-01.

Most recent recorded round closed around 2016-08-31.

Valuation (modeled)modeled

Provath models Spotlight Innovation, Inc. at approximately $48M (range $4.5M–$128M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.02× the median modeled value of Series C Pharmaceuticals companies in 2016–2018 (32 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 9 months.

Last raise 9.8 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.6× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 79% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 43% of those peers.

Closest niche peers: Amplyx Pharmaceuticals, Inc., Ligand Pharmaceuticals Inc, Homology Medicines, Inc., KSQ Therapeutics, Inc., TP Therapeutics, Inc..

Peoplefiled

4 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.